Update in Medical Therapy of Ulcerative Colitis

Katz, Seymour

doi:10.1097/00004836-200204000-00004

Cited by 17 publications

(15 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those adverse effects include nausea, vomiting, headaches, folate-dependent anemia, and abnormal sperm production. 10 Furthermore, there are significant hypersensitivity reactions to sulfasalazine such as anaphylaxis, fever, severe skin reactions, profound bone marrow suppression, and pancreatitis. Although most patients who experience an adverse reaction to the sulfasalazine can switch to other 5-ASA compounds without difficulty, approximately 10% to 20% of patients will have similar reactions to both agents.…”

Section: Aminosalicylatesmentioning

confidence: 99%

Medical and Surgical Management of Chronic Ulcerative Colitis

Cima

Pembérton²

2005

Arch Surg

View full text Add to dashboard Cite

Section: Aminosalicylatesmentioning

confidence: 99%

Medical and Surgical Management of Chronic Ulcerative Colitis

Cima

Pembérton²

2005

Arch Surg

View full text Add to dashboard Cite

“…The treatment of IBD has been extensively reviewed [4, 5, 92–99], and therefore only recent advances in conventional and unconventional therapy are dealt with here, focusing, in particular, on emerging approaches, such as, for instance, biological therapies for the management of these conditions.…”

Section: Therapymentioning

confidence: 99%

Inflammatory bowel disease: new insights into pathogenesis and treatment

Ardizzone

Porro

2002

Journal of Internal Medicine

155

View full text Add to dashboard Cite

Despite all the advances in our understanding of the pathophysiology of inflammatory bowel disease (IBD), we do not know the cause. Some of the most recently available data have been discussed here and yet it is now becoming increasingly accepted that immunogenetics play an important role in the predisposition, modulation, and perpetuation of IBD. The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation. The role of intestinal milium, and enteric flora in particular, appears to be of greater significance than previously held. A review is made of the main areas of research exploring the mechanisms more intimately associated with the development of IBD, providing advances in the agents currently used, and identifying a host of new therapeutic agents potentially interacting with or interrupting specific targets in the genesis of IBD.

show abstract

“…Cyclosporine is generally considered to be less safe than other IBD therapies because of the risk of serious side effects such as anaphylaxis, seizure, pneumocystis carinii pneumonia and permanent nephrotoxicity [Katz, 2005]. Moreover, potential easy use is limited by the need for close monitoring of drug serum levels because there is a narrow gap between the therapeutic and the toxic ranges [Cohen et al 1999].…”

Section: Management Of Axial Involvementmentioning

confidence: 99%

Management of arthropathy in inflammatory bowel diseases

Peluso

Manguso

Vitiello

et al. 2014

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

The most common extra-intestinal manifestation in patients with inflammatory bowel disease (IBD) is articular involvement, with a prevalence ranging between 17% and 39%. It is frequently characterized by an involvement of the axial joints but may also be associated with peripheral arthritis. The target of therapy in the management of arthritis associated with IBD is to reduce the inflammation and prevent any disability and/or deformity. This requires active cooperation between gastroenterologist and rheumatologist. The treatment of axial involvement has focused on the combination of exercise with nonsteroidal anti-inflammatory drugs. Immunomodulators have been efficacious in patients with peripheral arthritis and other extra-intestinal manifestations, but they are not effective for the treatment of axial symptoms of spondylitis. Tumor necrosis factor (TNF) α inhibitors have been proven to be highly effective in the treatment of IBD patients which are steroid-dependent or refractory to conventional therapy and in patients with associated articular manifestations. The treatment of peripheral involvement and/or enthesitis and/or dactylitis is based on local steroid injections, while sulfasalazine and/or low doses of systemic steroids may be useful in case of inadequate response to intra-articular steroids. Sulfasalazine induces only a little improvement in peripheral arthritis. Immunomodulators such as methotrexate, azathioprine, cyclosporine and leflunomide show their efficacy in some patients with peripheral arthritis and other extra-intestinal components. TNF-α inhibitors should be considered the first-line therapeutic approach when moderate-to-severe luminal Crohn's disease or ulcerative colitis is associated with polyarthritis. The aim of this review is to provide a fair summary of current treatment options for the arthritis associated with IBD.

show abstract

Update in Medical Therapy of Ulcerative Colitis

Cited by 17 publications

References 102 publications

Medical and Surgical Management of Chronic Ulcerative Colitis

Medical and Surgical Management of Chronic Ulcerative Colitis

Inflammatory bowel disease: new insights into pathogenesis and treatment

Management of arthropathy in inflammatory bowel diseases

Contact Info

Product

Resources

About